Nicotinamide adenine dinucleotide, a coenzyme critical for cellular energy metabolism that declines with age. NAD+ precursors like NMN and NR are studied as longevity interventions.

Mechanistic target of rapamycin, a key nutrient-sensing pathway that regulates cell growth and aging. Inhibiting mTOR (e.g., with rapamycin) has shown lifespan extension in multiple organisms.

A class of drugs that selectively eliminate senescent (aged, dysfunctional) cells to reduce inflammation and improve tissue function.

What is Epigenetic clock?

A biomarker based on DNA methylation patterns that estimates biological age, often more predictive of health outcomes than chronological age.

The period of life spent in good health, free from chronic diseases and disability associated with aging.

An immunosuppressant drug that inhibits the mTOR pathway. Research shows rapamycin may extend lifespan and improve age-related health outcomes in multiple species.

What is Biological age?

A measure of how well or poorly your body is functioning relative to your chronological age, assessed through biomarkers such as DNA methylation, telomere length, and blood panels.

What is Caloric restriction?

A dietary regimen that reduces calorie intake without malnutrition. Caloric restriction is one of the most studied interventions shown to extend lifespan across species.

Protective caps at the ends of chromosomes that shorten with each cell division. Telomere length is associated with aging and age-related diseases.

A state in which cells permanently stop dividing but resist death, accumulating with age and secreting inflammatory factors that damage surrounding tissue.

A second-generation epigenetic clock that predicts time to death and is considered one of the most accurate measures of biological aging.

What is Inflammaging?

Chronic, low-grade inflammation that increases with age and contributes to the development of age-related diseases including cardiovascular disease, diabetes, and neurodegeneration.

The large-scale study of proteins in biological systems. In longevity research, proteomics identifies blood protein signatures that predict biological age and disease risk.

What is Yamanaka factors?

A set of four transcription factors (Oct4, Sox2, Klf4, c-Myc) that can reprogram adult cells to a pluripotent state. Partial reprogramming with Yamanaka factors is being explored to reverse cellular aging.

Nicotinamide mononucleotide, a precursor to NAD+ that is widely studied as a supplement to boost cellular energy and combat age-related decline.

A gene-editing technology that allows precise modifications to DNA. In longevity research, CRISPR is used to study and potentially modify genes associated with aging.

A cellular housekeeping process where cells break down and recycle damaged components. Declines with age and is stimulated by fasting.

What is Intermittent fasting?

An eating pattern that cycles between periods of fasting and eating. Various protocols (16:8, 5:2) are studied for metabolic, cardiovascular, and longevity benefits.

What is Zone 2 cardio?

Low-intensity aerobic exercise performed at roughly 60–70% of maximum heart rate, primarily using the aerobic energy system. Associated with mitochondrial health and longevity.

Geographic regions identified by researchers where people consistently live longer and healthier lives than average, including Sardinia, Okinawa, and Loma Linda.

New Cancer Treatments Show Promise at ASCO Meeting

Researchers announced new findings on Eikon Therapeutics’ latest cancer treatments, which will be presented at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting. The company is focusing on three main drug candidates: EIK1001 for non-small cell lung cancer (NSCLC) and advanced melanoma, EIK1003 for various solid tumors, and EIK1005 for tumors with specific DNA replication issues. These presentations will provide updated data on the safety and effectiveness of these treatments, potentially offering new hope for patients battling serious cancers.

This research is particularly relevant for individuals seeking effective cancer therapies. If successful, these treatments could improve outcomes for patients with advanced cancers, including those with NSCLC, breast, ovarian, prostate, or pancreatic cancers. The trials aim to optimize treatment strategies and enhance patient selection, which could lead to better overall health and survival rates for those diagnosed with these conditions.

The evidence presented at ASCO will stem from various stages of clinical trials. EIK1001 is undergoing Phase 2 and 3 trials, while EIK1003 is in Phase 1 and 2 studies. EIK1005 is still in the early development phase, making these findings promising but not yet proven in larger populations. As such, while the research shows potential, it is essential to keep expectations in check until more conclusive results are available.

For those interested in the latest cancer treatments, staying informed about these developments is crucial. Engaging with healthcare providers about novel therapies and clinical trial options could be beneficial, especially for individuals facing advanced cancer diagnoses.

Source: globenewswire.com